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The retinoid X receptor agonist bexarotene promotes remyelination in patients with
multiple sclerosis. Murine studies have also demonstrated that RXR agonists have anti-
inflammatory effects by enhancing the ability of all-trans-retinoic acid (atRA) to promote T-
regulatory cell (Treg) induction and reduce Th17 differentiation in vitro. By stimulating
human naïve CD4 T-cells in the presence of Treg or Th17 skewing cytokines, we show
that bexarotene also tips the human Treg/Th17 axis in favor of Treg induction, but unlike
murine cells this occurs independently of atRA and retinoic acid receptor signaling. Tregs
induced in the presence of bexarotene express canonical markers of T-regulation and are
functionally suppressive in vitro. Circulating Treg numbers did not increase in the blood of
trial patients receiving bexarotene; we believe this is because Treg induction is likely to
occur within tissues. These findings lend support to developing RXR agonists as
treatments of autoimmune diseases, in particular multiple sclerosis.
Keywords: T cells, Th17 & Tregs cells, multiple sclerosis, autoimmunity, retinoid X receptor (RXR), retinoidsINTRODUCTION
Bexarotene, a pan retinoid X receptor (RXR) agonist licensed for use in humans as a treatment of
cutaneous T-cell lymphoma, has recently been shown to promote remyelination in multiple
sclerosis (MS). Although the Cambridge Centre for Myelin Repair (CCMR)-one trial failed to
meet its primary endpoint pre-planned analyses demonstrated that bexarotene promoted the
remyelination of the most demyelinated lesions, particularly in grey matter (as determined
radiologically). In addition, conduction in the visual pathway improved in patients randomized
to bexarotene, providing further evidence of its pro-remyelinating effect (Reference Lancet
Neurology manuscript).org August 2021 | Volume 12 | Article 7122411
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work done in rodent s , wh ich demons t ra ted tha t
oligodendrocytes express RXR (specifically RXR-g) during
active remyelination, and that remyelination can be promoted,
in vitro and in vivo, following administration of RXR
agonists (1).
Murine studies have also demonstrated that RXR agonists can
enhance the ability of all-trans-retinoic acid (atRA), the primary
active metabolite of vitamin A, to promote Treg induction
(iTregs), and reduce Th17 differentiation in vitro, following
stimulation of naïve CD4 cells in the presence of TGF- b (2).
At physiological concentrations, atRA binds to the retinoic acid
receptor (RAR) which is bound to DNA as a heterodimer with
RXR in regions called retinoic acid response elements (RAREs).
Binding of atRA to the RAR/RXR heterodimer leads to a
conformational change, which in turn promotes down-stream
transcription of hundreds of genes (3), including those involved
in the induction of Tregs.
In contrast to atRA, RXR ligands are unable to promote the
differentiation of murine naïve T cells to iTregs directly. Instead,
they act synergistically with atRA to promote FOXP3 expression
(2). In this way RXR is said to act as a conditionally permissive
binding partner to RAR – that is, whilst RXR ligand binding is
unable to trigger down-stream signaling, maximal receptor
signaling and transcriptional activity is achieved when RAR
and RXR ligands bind simultaneously (2, 3).
Here we sought to determine if the RXR agonist bexarotene,
licensed for use in humans and recently shown to have pro-
remyelinating effects in MS, has similar immunoregulatory
effects on the human iTreg/Th17 axis.METHODS AND MATERIALS
Cell Preparation
Human PBMCs were isolated from the fresh buffy coats of whole
blood of healthy donors by Ficoll-Paque Plus centrifugation (GE
Healthcare, Sweden). PBMCs were counted by trypan blue
exclusion and resuspended in PBS. Naive CD4+ T cells were
either isolated through magnetic activated cell sorting (MACS)
or fluorescence-activated cell sorting (FACS). With MACS, naive
T cells were isolated through negative selection from total PBMC
using the naive CD4+ T Cell Isolation Kit, human (Miltenyi, 130-
094-131), according to the manufacturer’s instructions. With
FACS, naive CD3+CD4+CD127+CD25lowCD45RA+CD62L+
CD27+CCR7+ were isolated from CD4+ enriched PBMCs
following negative isolation using CD4+ T cell Isolation Kit,
human (Miltenyi , 130-096-533), using a BD Influx
(Supplementary Figure 1). Staining for FACS was done on
cell surface markers, live/dead, CD3, CD4, CD127, CD25,
CD62L, CD45RA, CD27 and CCR7 with relevant mAbs
(BioLegend and BD). CD25high “nTregs” and CD3+CD4+
CD127+CD45RA-CD62L- “Teffs” were also isolated from the
same CD4+ enriched population and were cryopreserved in 10%
DMSO (Sigma-Aldrich) and 90% FBS (Life Technologies,
Thermo Fisher Scientific), for later use in suppression assays.Frontiers in Immunology | www.frontiersin.org 2Naive CD4+ T cells were cultured at 5% CO2/37°C in serum-free
X-Vivo 15 medium (Lonza).
iTreg Differentiation
Naive CD4+ T cells were plated under iTreg differentiation
conditions at 1.0x105 cells/well in 96 U-bottom well plates
(Falcon). For cell stimulation, plates were coated at least
5 hours prior to use with 5 ug/ml plate-bound anti-CD3
antibody (clone OKT3; BioLegend, LEAF grade), which is then
washed off with PBS, with 1 ug/ml soluble anti-CD28 antibody
(BioLegend, LEAF grade) and 5 ng/ml IL-2 (carrier-free; Tocris
R&D Systems) added with cells. Cells treated with only these
functioned as the mock control. For iTreg induction, TGF- b
(5ng/ml; carrier-free; Tocris R&D Systems), anti-IFN g antibody
(2 ug/ml; clone MD-1, Biolegend), bexarotene (1 µM, Abcam) or
atRA (100 nM; Sigma-Aldrich) were added additionally. The
DMSO control (for bexarotene, atRA and AGN190) had no
effect on FOXP3 expression. Cells were incubated for 7 days
unless otherwise stated.
Th17 Cell Differentiation
After either MACS or FACS isolation, naive cells were plated
under Th17 differentiation conditions at 5x105 cells/well in 96 U-
bottom well plates (Falcon). For cell stimulation, plates were
coated at least 5 hours prior to use with 3 ug/ml plate-bound
anti-CD3 antibody (clone OKT3; BioLegend, LEAF grade),
1 ug/ml soluble anti-CD28 antibody (BioLegend, LEAF grade)
and 2 ng/ml IL-2 (carrier-free; Tocris R&D Systems). Cells
treated with only these functioned as the mock control. For
Th17 induction, TGF- b (30 ng/ml; carrier-free; Tocris R&D
Systems), IL-6 (30 ng/ml; carrier-free; Tocris R&D Systems),
IL-1 b (10 ng/ml; carrier-free; Tocris R&D Systems), IL-23
(50 ng/ml; carrier-free; Tocris R&D Systems), anti-IFN g
antibody (2 ug/ml; clone MD-1, Biolegend), anti-IL-4 antibody
(2 ug/ml; clone MD-1, Biolegend), bexarotene (1 µM, Abcam),
or atRA (100 nM; Sigma-Aldrich) were added additionally. The
DMSO control (for bexarotene, atRA and AGN190) had no
effect on IL-17A cytokine expression. Cells were incubated for
7 days unless otherwise stated.
In Vitro Suppression Assays
For use in suppression assays, on day 7 iTregs were washed twice
in PBS and their viability and count assessed with trypan blue
exclusion. Cells were then allowed to rest for 3 hours in fresh,
serum free X-Vivo 15 media prior to addition into suppression
assay cell culture at 5% CO2 at 37°C. The mock IL-2 treated
control cells were also washed, counted, and rested in the same
manner as for iTregs. Cryopreserved Teffs from donors were
thawed quickly within a water bath at 37°C, washed and rested
for 4 hours at 5% CO2 37°C. To discriminate between Teffs and
Tregs in the suppression assay, Teffs were labelled with 5 mM cell
proliferation dye EFV450, and iTregs were labelled with 5 mM
cell proliferation dye BV670 (both from eBioscience). Teffs were
plated at 5x104 cells per well in duplicate, with and without
iTregs, in serum free X-Vivo 15 media alone. Cells were cultured
for 3 days. For the final analysis, dead cells were excluded using
dead cell exclusion staining (Zombie NIR; eBioscience), and cellsAugust 2021 | Volume 12 | Article 712241
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suppressive capacity, iTregs were titrated up so that the iTreg/
Teff ratio was 1:1 to 3:1 and 6:1. Duplicate control wells of CD4+
T cells without stimulus, and Tregs, at various dilutions, with and
without stimulus, were also cultured. Treg Suppression Inspector
beads (Miltenyi Biotec) were used to stimulate the assay,
according to the manufacturer’s instructions.
Flow Cytometry and Antibodies
Viability Staining
Cells taken from culture were washed once with 1 mL PBS and
resuspended in 100 ul PBS. Cells were then stained with LIVE/
DEAD™ Fixable Aqua Dead Cell Stain Kit (Thermo Fisher
Scientific) for 30 minutes, in the dark at 4°C. Cells were then
washed twice with 1 mL of FACS buffer (0.5% BSA/PBS) and
taken for subsequent cell surface marker staining.
Surface Staining
Cell surface staining was performed in the dark at 4°C in
antibody dilutions in FACS buffer for 30 minutes, with a final
staining volume of 100 ul. Cells were then washed twice with 1
mL PBS and either taken for flow cytometry analysis or used for
subsequent intracellular staining
Cell Permeabilization and Intracellular Staining
Cell permeabilization and fixation was performed using the Foxp3
Staining Buffer Set (eBioscience), according to the manufacturer’s
instructions at room temperature for 40 minutes. Intracellular
staining was then performed, according to manufacturer’s
instructions in the dark at 4°C. To measure intracellular
cytokines, cells were stimulated for 4h prior to staining with 1x
Cell Activation Cocktail (PMA, ionomycin, and Brefeldin A; 500X).
Antibodies (Anti-Human)
The complete list of antibodies used is as follows and were purchased
from eBioscience, BD Biosciences or BioLegend, unless otherwise
indicated. Brackets indicate (fluorochrome, antibody clone).
Sorting Panel
CD45RA (AF488; HI100), CCR7 (PerCP-Cy5.5; G043H7),
Zombie Aqua (live/dead stain), CD27 (BV605; 323), CD3
(BV650; UCHT1), CD62L (BV786; DREG-56), FOXP3 (PE;
259D, 259D/C7, 206D), CD127 (PE-Cy7; eBioRDR5), CD25
(APC; M-A251) and CD4 (APC-R700; RPA-T4), and for
bisulfite sequencing only - FOXP3 (PE; 259D, 259D/C7, 206D).
iTreg Staining
FOXP3 (PE; 259D), CD25 (APC, 2A3), CD3 (BV650; UCHT1),
CD4 (APC-R700, RPA-T4), CD127 (PE-Cy7; eBioRDR5).
Th17 Staining
CD3 (BV650, UCHT1), CD4 (APC-R700, RPA-T4), CD25
(APC, 2A3), CD127 (PE-Cy7, eBioRDR5), IFN-y (BUV395;
B27), IL-17 (PE, SCPL1362) IL-21 (BV421; 3A3-N2.1).
CCMR-One
FOXP3 (PE; 259D), CD25 (BV421, 2A3 and MA251), CCR6
(BV650, 11A9), CCR4 (BB700, 1G1), CD3 (BV605, SK7),Frontiers in Immunology | www.frontiersin.org 3CD45RA (BV785, HI100), HELIOS (FITC, 22F6), CD8 (PE-Cy5,
RPA-T8), CD4 (APC, RPA-T4), HLA-DR (AFR-700, L243), T.S.
monocyte blocker, CD127 (PE-Cy7, PCH101), CD27 (APC-eFluor
780, 0323), CCR4 (PerCP eFluor 710, D8SEE).
Acquisition
Acquisition was performed on a BD LSR Fortessa and
compensation was performed manually using single stained
color controls. Cell sorting was performed on BD Influx under
sterile conditions. FACS data was analyzed using FlowJo (V10.1)
and sort reports were collected for each cell sort experiment.
Enzyme-Linked Immunosorbent Assay
(ELISA) Measurements
IL-17a ELISAs were performed using Human IL-17A (homodimer)
ELISA Ready-SET-Go!™ Kit (Invitrogen™; eBioscience™),
according to the manufacturer’s instructions. Plates were coated
the day prior to beginning the ELISA and kept covered at 4°C.
Analysis of TSDR Methylation
CD4+ CD25+ Foxp3+ iTregs and CD4+ CD25+ Foxp3− non-Tregs
were sorted by FACS from “bulk iTreg cultures” from 4 male and 4
female donors, then stored immediately as a dry frozen pellet for
bisulfite sequencing. DNA of FACS sorted iTregs and control cells
from female and male donors was isolated using the DNeasy Blood
and Tissue Kit (Qiagen), according to the manufacturer’s
instructions. Bisulfite sequencing was performed in house, as
previously described (Rainbow et al., 2015). Six replicates of 3000
cells per replicate (5 ng DNA) were analyzed from a single donor
and the median (with range) reads with eight or nine sites
demethylated at FOXP3 for the replicates, is reported.
Statistical Analysis
All flow cytometry data were analyzed in-house with FlowJo (v10.1);
all other data analyses and statistical fitting were performed in-
house with GraphPad (Prism). Where appropriate, ANOVA and
two-tailed t-tests were performed to assess for differences in Foxp3
protein expression between wells and experiments. One-way
ANOVAs were corrected using Tukey’s multiple comparisons
test. Repeated measures one-way ANOVAs and two-tailed t-tests
were corrected using Šidák’s correction. The test and corresponding
correction performed is indicated in each figure legend.
Study Approval
Healthy Controls
Peripheral blood mononuclear cells (PBMCs) were isolated from
anonymous healthy donor buffy coats, which were obtained from
the Addenbrooke’s Hospital NHS blood and transplant service
(Cambridge, United Kingdom). All individuals gave written
consent, and the study was approved by a local ethical review
committee (REC: 11/EE/0007).
CCMR-One Patients
Individuals aged 18-50 years with relapsing remitting multiple
sclerosis, stable on dimethyl fumarate, who were randomized on
the CCMR-One study to bexarotene (300mg/m2 body surfaceAugust 2021 | Volume 12 | Article 712241
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under REC 15/LO/0108. For full details of the CCMR-One
protocol please refer to the published trial manuscript (Ref).RESULTS
Bexarotene Promotes the Induction of
Human Tregs Independent of RAR
Activation
To determine the effect of bexarotene on human iTreg induction
FACS-sorted naïve CD4 T conventional (Tconv) cells (CD3+
CD4+CD127+CD25lowCD45RA+CD62L+CD27+CCR7+;
Supplementary Figure 1) were cultured for 7 days in serum-free,
and therefore atRA free media, under iTreg inducing conditions
(anti-CD3/28 stimulation plus IL-2 and TGF-b) with and
without the addition of bexarotene (1 µM), atRA (100nM) or
both. As a negative control, naïve cells were also stimulated with
anti-CD3/28 beads in the presence of IL-2 only (“IL-2 control”).
In contrast to what was expected from murine studies,
bexarotene alone was sufficient to increase Treg induction as
measured by percent FOXP3 expression (Figure 1A, from
21.52% to 39.25% p=0.0038). This increase was equivalent to
that seen following the addition of atRA (41.29% p=0.0013). No
synergistic effect between bexarotene and atRA was observed
(Figure 1B). FOXP3 expression within the iTreg population was
unaffected by culture conditions (Supplementary Figure 2). Cell
viability was high (>90% for FOXP3+ cells, and >70% for
FOXP3- cells) in the presence of bexarotene (1 µM) and/or
atRA (100nM) and was equivalent to that seen in control iTreg
conditions - confirming increased iTreg differentiation rather
than selective cell loss (Supplementary Figure 3A).
Next a dose ranging experiment was performed which
demonstrated that bexarotene and atRA caused a similar dose-
dependent increase in iTreg induction, resulting in up to ~2.5
fold more FOXP3+ cells (Figures 1C, D). At concentrations
above 20µM bexarotene inhibited iTreg differentiation and
resulted in significant cell death (>95% dead; data not shown).
Although all assays were performed in serum-free media, and
therefore atRA free conditions; to be certain that bexarotene was not
driving Treg differentiation via a RAR dependent mechanism, the
above assays were repeated following pre-incubation with AGN
193109, a potent and selective RAR antagonist (Figure 1E). Pre-
incubation with AGN fully blocked the pro-iTreg inducing effects of
atRA (% iTregs 54.78% vs 22.75%, p=0.0066, compared to iTreg
conditions alone = 32.27%). In keeping with its RAR-independent
mode of action, the addition of AGN had no effect on increased
iTreg differentiation in the presence of bexarotene (% iTregs 58.63%
vs 57.60%). AGN did not affect cell viability at the concentrations
used (data not shown).
9-cisRA and the Synthetic RXR Agonist,
NRX 194204 Also Promote Human iTreg
Differentiation In Vitro
To determine if the effects seen were specific to bexarotene, or a
generic effect of RXR agonism, FACS sorted naïve T-cells wereFrontiers in Immunology | www.frontiersin.org 4cultured in serum-free media under iTreg inducing conditions
(IL-2 and TGF-b) with and without the addition of a synthetic
RXR agonist (NRX 194294) or 9-cisRA (a metabolite of Vitamin
A, and the primary endogenous RXR agonist).
As seen with bexarotene, both 9-cisRA and NRX enhanced to
the same degree naïve T-cell differentiation to iTregs
independently of RAR agonism, and neither had a synergistic
effect with atRA (% iTregs with 9-cisRA= 58.93, % iTregs with
NRX= 32.56%; Figures 1F, G).
Bexarotene Induced Tregs Are
Suppressive In Vitro
In addition to expressing FOXP3, the regulatory phenotype of
the iTregs was confirmed through suppression assays. In brief,
naïve CD4+ T cells were isolated from healthy donors and
following 7 days of iTreg induction protocol with and without
bexarotene, cells were co-cultured with Teffectors for 3 days and
proliferation measured.
Tregs induced in the presence of bexarotene were as
suppressive as Tregs induced in standard Treg induction
conditions (59.2% suppression at a ratio of 1:6, Teff:iTregs)
(Figure 2A). This suppressive effect was demonstrated to be
titratable. At ratios of 1:1, 3:1 and 6:1, there was a non-statistically
significant trend for iTregs induced in the presence of bexarotene
to be more suppressive than iTregs induced without bexarotene
(+9.7%, +13.1% and +7.1% respectively). However, this is likely to
reflect increased percentage of FOXP3+ cells within the iTregs in
bexarotene-induced conditions, as shown in Fig. 1B. Overall,
these data confirm that iTregs induced in the presence of
bexarotene are functionally suppressive.
Phenotypic Differences Between nTregs
and iTregs Induced in Different Conditions
To explore any phenotypic differences between human nTregs
and iTregs induced under different conditions, the expression of
several Treg signature molecules was analyzed in iTregs, induced
in the presence of atRA or bexarotene versus nTregs (ex vivo,
unstimulated and stimulated) (Figure 2B).
The proportion of cells expressing the inhibitory receptors
CTLA4 and PD1 was higher in iTregs compared to ex vivo
nTregs (74.72% vs 2.76% and 92.71% vs 16.56% respectively, Fig
2A). Furthermore, density of CTLA4 and PD1 expression was
more than four-fold higher in iTregs (MFI: 17,512 vs 3805.5 and
12,857 vs. 3005.0 respectively). Following nTregs stimulation
surface CLTA4 expression increased significantly but remained
slightly lower than iTregs induced in the presence of bexarotene
and/or atRA. In contrast, nTreg PD1 expression remained very
low post-stimulation.
Comparing between iTreg conditions, both bexarotene and
atRA increased CTLA4 expression (MFI of positive cells) but had
no effect on PD 1 expression.
Compared to nTregs (ex vivo and stimulated), fewer iTregs
expressed the inhibitory molecule TIGIT (59.48%, 41.11% and
19.42%, respectively), but those expressing TIGIT did so at a
higher density (MFI 4914.8 vs 2575.25; p=<0.0001). However,
this difference was lost when nTregs were stimulated. In contrast,August 2021 | Volume 12 | Article 712241
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competes against TIGIT for binding to their shared ligands
(CD155 and CD122) was found to be increased on iTregs
compared to ex vivo and activated nTregs, both in terms of
percent expression and MFI. Treg induction in the presence of
bexarotene, atRA or both reduced TIGIT (p=0.034, p=0.048,
p=0.040) and CD226 (p=0.002, p=0.004, p=0.008) expression on
a per-cell basis but did not affect the percent positive.
A higher percentage of bexarotene or atRA induced iTregs
expressed HELIOS, 83.68% and 81.40%, respectively versus
70.975% in untreated iTregs, this increase was not observed in
cells cultured with both compounds, or DMSO control (as bothFrontiers in Immunology | www.frontiersin.org 5bexarotene and atRA are reconstituted in DMSO). bexarotene
and atRA had no effect upon the per-cell expression of HELIOS.
Bexarotene Does Not Alter the FOXP3
TSDR of iTregs
To address the question of iTreg lineage stability, we assessed
methylation status of the FOXP3 Treg specific demethylation
region (TSDR) within intron 1 of FOXP3 using bisulfite
sequencing (4). Tregs with a highly demethylated TSDR are
known to exhibit stable FOXP3 expression whereas cells that
transiently express FOXP3 are highly methylated within this
region and may lose Treg associated activity. As FOXP3 is on theA
B C D
E F G
FIGURE 1 | RXR agonists promote human iTreg differentiation independent of RAR signaling. (A) Gating strategy and example dot plots showing iTreg induction
following culture of naï ve T cells for 7 days in iTreg skewing conditions +/- bexarotene (1 mM), +/- atRA (100 nM) or both (B) Summary data for n=6 experiments (C, D)
percent iTreg induction over a range of atRA and bexarotene concentrations. (E) Co-culture with the RAR antagonist AGN reverses increased iTreg induction seen in the
presence of atRA, but not Bexarotene. (F, G) The RXR agonists 9CisRA and NRX194204 also promote human iTreg differentiation in vitro. Shown are mean values ±
SEM. Significance calculated using a repeated measures one-way ANOVA. Šidák’s correction was performed. *p < 0.05, **p < 0.01, ***p < 0.001 ns, not significant.August 2021 | Volume 12 | Article 712241
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FIGURE 2 | Comparison of iTregs vs donor-matched nTregs. (A) Percent suppression of CD3/CD28 stimulated Teff in the presence of iTregs or iTregs induced in the
presence of bexarotene (two-tailed ANOVA, ns). (B) Phenotypic characteristics of iTregs, induced +/-bexarotene, +/-atRA or both vs. donor-matched nTregs stained
immediately (ex-vivo) or following culture for 7 days (5 mM CD3, 1 mM CD28, 1 ng/ml IL-2). Shown are mean values ± SEM. iTreg, n = 4. ex vivo iTreg, n=4. nTreg +
stim, n = 3. Significance was calculated with one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Tukey’s correction). (C) FOXP3 TSDR methylation,
determined by bisulfite sequencing, of iTregs and iTregs induced in the presence of bexarotene vs. donor-matched nTregs. Owing to X inactivation FOXP3 TSDR
demethylation is ∼50% lower in females compared to males. Plots from two representative donors (one male, one female) are shown; total donors n = 6.
Gaunt et al. Bexarotene Promotes Human iTreg DevelopmentX-chromosome, X-chromosome inactivation approximately halves
the level of TSDR demethylation seen within female donors.
As expected, flow sorted nTregs were fully demethylated
whereas iTregs displayed a methylated FOXP3 TSDR,
comparable to that of FOXP3- cells from the same culture. The
addition of 1 mM bexarotene had no effect on the TSDR
methylation of iTregs (Figure 2C).
Bexarotene Suppresses the Induction of
Th17 Cells
In addition to enhancing the conversion of FOXP3+ iTregs in
vitro from naive CD4+ T cells, RXR agonists have been reportedFrontiers in Immunology | www.frontiersin.org 7to inhibit murine Th17 development in vitro and in vivo in an
RAR independent manner. Here we sought to determine
whether bexarotene was capable of suppressing human Th17
induction in a similar manner.
Briefly, MACS separated naive CD4+ lymphocytes stimulated
in serum free media, with or without the addition of bexarotene
and/or atRA, under Th17 skewing conditions (namely in the
presence of TGF-b, IL-6, IL-1B, IL-23 and with neutralizing
antibodies against IL-4 and IFN-g).
Both bexarotene and atRAwere equally able to suppress human
Th17 cell differentiation in vitro, as measured by intracellular
IL-17A cytokine staining (Figures 3A, B) and IL-17A secretionA
B C
D
FIGURE 3 | Bexarotene significantly reduces the differentiation of CD4+ naive lymphocytes into Th17 IL-17a+ cells in vitro. (A) Representative dot plots showing
intracellular Th17 and IFN-g following culture of human naiïve CD4 cells in Th17 skewing conditions +/- bexarotene, +/-atRA or both. (B) Summary data showing
percent IL-17+ cells as a percent of total live CD4 cells at the end of culture (n = 7). (C) Supernatant IL-17a as measured at day 7 (n = 7). Shown are mean values ±
SEM. Significance was calculated with repeated measures one-way ANOVA. Šidaák’s correction was performed. **p < 0.01, ****p < 0.0001.August 2021 | Volume 12 | Article 712241
Gaunt et al. Bexarotene Promotes Human iTreg Development(through ELISA of supernatant) (Figures 3B, C). No synergistic
effect was observed, with bexarotene and atRA together
suppressing Th17 cell differentiation to the same degree as found
with either bexarotene or atRA alone. Cell viability was high (>90%
for IL-17A+ cells, and >65% for IL-17A- cells) in the presence of
bexarotene (1 µM) and/or atRA (100nM) and was not significantly
different than that seen in Th17 control conditions - confirming
reduced Th17 differentiation rather than selective cell loss
(Supplementary Figure 3B).
These findings demonstrate for the first time that an RXR
specific agonist can actively inhibit human Th17 differentiation
and the secretion of IL-17A following stimulation in vitro.
No Differences Are Observed in the
Peripheral Blood of Individuals Treated
With Bexarotene on the CCMR-One Study
Patients enrolled within the CCMR One trial (reference Lancet
Neurology manuscript) receiving bexarotene, in addition to
standard MS treatment with dimethyl fumarate, were
immunophenotyped to examine if the immunomodulatory
effects of bexarotene could be replicated in vivo - see Table 1
patient for demographic information. PBMCs were collected
from patients randomized to receive bexarotene pre- and at
months 2, 4 and 6 of treatment. Serum samples were collected at
the same time points for measurement of IL-17A.
The frequency of CD4+ T cells and absolute CD4 counts were
unchanged by bexarotene treatment (Figure 4A, Supplementary
Figure 4). In keeping with treatment with the MS disease
modifying drug dimethyl fumarate 2 of the 5 patients had
lymphocyte counts below the lower limit of normal (LLN -
1.10x109/L). No difference was found in the frequency or
absolute numbers of circulating CD4+Tregs (Figures 4B–E) or
Th17 cells (Figures 4G, I, J) (identified by intracellular flow
cytometry) following treatment with bexarotene, and serum IL-
17A levels were also unchanged (Figure 4H). Furthermore, in
line with our in vitro data, no difference was found in the
methylation status of Tregs from both male and female
donors (Figure 4F).DISCUSSION
We have demonstrated that the RXR agonist bexarotene, which has
recently been shown to promote remyelination in individuals with
MS has immunomodulatory effects on human cells - promoting
naive CD4+ T-cell differentiation into Tregs and suppressing theirFrontiers in Immunology | www.frontiersin.org 8differentiation into Th17 cells. Our findings lend support to the
development of RXR agonists as a therapy for MS.
Despite opposing functions, Th17 cells and iTregs share a
closely related developmental pathway mediated by TGF-b. In
the presence of TGF-b and IL-6 or IL-21 (produced by activated
T-cells and DCs) naive CD4+ cells differentiate into Th17 cells.
However, in the absence of proinflammatory cytokines, and in
the presence of TGF-b and IL-2, naive cells differentiate into
Tregs. TGF-b induces SMAD2 and SMAD3 phosphorylation
which in turn activate FOXP3, which drives cells towards the
Treg lineage (in contrast IL-6 inhibits SMAD signaling). In
addition, IL-2 phosphorylates STAT5 which activates FOXP3.
iTregs induced in vivo are termed “pTregs” (for peripherally
induced), to distinguish them from thymically derived Tregs
(also known as naturally occurring or “nTregs”). It is thought
that pTregs may constitute a significant proportion of Tregs in
the periphery particularly at certain sites such as the lamina
propria and maternal placenta where they may maintain
tolerance against commensal bacteria and the developing fetus
(5). In addition to their shared dependency on TGF-b, many
studies have reported plasticity between iTregs and Th17 cells
under certain conditions. For example, studies tracing the fate of
IL-17+ cells in the gut, reveal that many at some point express
FOXP3 (6). Given this, it is not surprising that the Th17/Treg
balance has been shown to play a critically important role in
many autoimmune diseases, including MS (7).
In contrast to published murine studies, we have shown that
bexarotene promotes human iTreg differentiation independent of
RAR signaling. Therefore, RXR supplementation alone should be
sufficient to promote iTreg induction in patients. Independence
from RAR signaling was shown both by culturing cells in
serum-free, and therefore atRA free media, and by using the
pan-RAR antagonist AGN193109. Also counter to murine data
is our observation that bexarotene and atRA do not work
synergistically to enhance human iTreg differentiation in vitro.
One possibility is that atRA was used at concentrations reaching
the maximum threshold for atRA enhancement of human iTregs
differentiation. atRA is thought to promote iTreg differentiation
through enhancing TGF-b driven SMAD3 signaling and inhibiting
the activity of IL-6 and IL-23 (8), meaning it is possible that these
mechanisms were saturated leaving bexarotene unable to promote
further atRA-mediated enhancement. In addition to RXR forming
a heterodimer with RAR, it can also form a homodimer or
dimerize with alternative binding partners - including the 1a,25-
(OH)2 vitamin D3 receptor (VDR), peroxisome proliferator-















1 40 F 1.5 1.61 1.56 1.09 1.33
2 40 F 1.5 0.96 0.81 0.75 1.21
3 42 F 6 1.66 1.68 1.75 1.89
4 49 M 1.5 1.29 1.16 1.09 1.24
5 37 F 1 0.68 0.74 0.63 0.87August 2021 | Volume 12 | Article 712241
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farnesoid X receptor (FXR) (9).
We have not determined through which receptor-dimer
complex bexarotene promotes iTreg differentiation. However,
as it occurs independently of RAR engagement it must do so
either through RXR/RXR homodimers, or via permissive nuclear
receptors, such as PPAR or LXR. Evidence in support of PPARFrontiers in Immunology | www.frontiersin.org 9engagement comes from studies showing that PPAR-a and
PPAR-g agonists also promote FOXP3 expression and TSDR
demethylation in CD4+CD25− T cells upon TCR stimulation in
the presence of TGF-b and IL-2 (10).
Compared to thymically derived nTregs (ex vivo or activated),
iTregs (induced in all conditions, including bexarotene) expressed








FIGURE 4 | Peripheral blood immune phenotyping of patients randomized to receive bexarotene on the CCMR-One trial. Samples were analyzed at baseline, then
at months 2, 4 and 6 following treatment. (A) Frequency of CD3+CD4+ cells as a percent of total lymphocytes. (B) Frequency of CD25hiCD127−FOXP3+ Tregs as
percent of CD4+ cells. (C) Frequency of Helios+ cells as a percent of CD25hiCD127−FOXP3+ Tregs. Shown are mean values ± SEM, n=5. (D) Absolute Treg counts
as defined by CD4+CD25hiCD127low surface phenotype. (E) Representative longitudinal plots of Treg gating and quantification. FOXP3 and HELIOS expression for
these populations are also shown. (F) FOXP3 TSDR methylation of flow sorted, circulating CD4+CD25hi CD127low Tregs pre- and post-bexarotene (n=5; two
representative donors are shown). (G) Frequency IL-17a+ cells, (H) IL-17a supernatant concentration and (I) absolute Th17 cell counts (as measured by IL-17a
positivity). (J) Representative longitudinal plots of intracellular IL17 and IFN-g in CD3+CD4+ cells, from patients pre- and post-bexarotene, following stimulation with
PMA + Ionomycin + Brefeldin A. Each sample was run in duplicate. For further information regarding CCMR-One subject demographics, refer to Table 1.August 2021 | Volume 12 | Article 712241
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CTLA-4 expression was further increased by exposure to
bexarotene or atRA. Cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) is a crucial inhibitory molecule and homolog to the co-
stimulatory molecule CD28, with which it shares ligands (CD80 and
CD86 expressed on APCs). Binding of CD80/86 (on antigen
presenting cells) to CD28 on T-cells provides a costimulatory
signal, whereas CTLA-4 captures CD80/86 from the surface of
APCs by transendocytosis, preventing CD28 engagement and T-cell
activation (11). PD-1 interactions with PD-L1 and PD-L2 also
down-modulate T-cell immune responses (12). In contrast to
CTLA-4 and PD-1, significantly fewer iTregs expressed the co-
inhibitory molecule TIGIT (T cell Ig and ITIM domain) compared
to nTregs, although iTregs expressing TIGIT did so at a higher level.
Expression of the co-stimulatory molecules CD226 was also
increased on iTregs (percent and per-cell expression) compared to
nTregs, although per-cell expression was slightly lower when Tregs
were induced in the presence of bexarotene and/or atRA. Similar to
CD28 and CTLA-4, CD226 and TIGIT share and compete for
ligands expressed on APCs (CD112 and CD155) promoting or
inhibiting T-cell activation respectively (13, 14). Despite high
CD226:TIGIT expression, and perhaps as a consequence of high
PD-1 and CTLA-4 expression, iTregs induced in the presence of
bexarotene were found to be at least as suppressive in vitro as iTregs
induced in standard conditions.
In addition to promoting iTreg differentiation, we have shown
that bexarotene is also capable of suppressing human Th17
development in vitro, as measured through intracellular IL-17A
staining and changes in supernatant IL-17A. This is the first report
using human cells and is keeping with murine studies where RXR
ligands have been shown to suppress Th17 development. Two such
studies report that RXR ligands are able to suppress Th17
development, attenuate active and Th17 mediated passive EAE and
suppress the numbers of CD4+ lymphocytes capable of secreting pro-
inflammatory cytokines (3, 15). Furthermore, RXR ligands have been
shown to reduce the expression of cell activation markers Ki-67 and
CCR6 on Th17 cells which is required for entry into the central
nervous system (CNS). These results are encouraging for diseases
such as MS, thought to be driven by aberrant regulation of Th17 cell
responses that are found with increased frequency in the periphery
and the CNS of patients (16, 17).
In this study, we took advantage of access to blood samples
from individuals with MS receiving bexarotene as participants on
the CCMR-One phase 2a trial, to explore the effects of
bexarotene in vivo. Disappointingly our in vitro observations
were not mirrored in the blood of individuals receiving
bexarotene. This may be because, at the dose given (300mg/m2
body surface area per day, for 6 months) bexarotene is unable to
promote iTregs in vivo. However alternatively this may be due to
the fact that bexarotene is likely to exert its effects at sites of CD4
naive cell activation and differentiation (i.e. within lymph nodes
and tissues) and therefore would be unlikely to affect circulating
Treg/Th17 numbers (18). Our results are also in keeping with
findings with use of bexarotene in cutaneous T cell lymphoma
(CTCL), where no change in the number of circulating Tregs was
found in peripheral blood (19), although in this study “Tregs”
were defined purely on the basis of CD25hi expression.Frontiers in Immunology | www.frontiersin.org 10Bexarotene was poorly tolerated in CCMR-One (reference
Lancet Neurology manuscript). Of the 32 patients dosed in
Cambridge, 16 developed central hypothyroidism and 14
developed elevated triglycerides, both well recognized side-effects
of bexarotene. Given this, it is unlikely that bexarotene will progress
further into clinical development as a therapeutic strategy in MS.
However, these results do provide hope and momentum behind the
development of other RXR-isoform specific agonists.
In summary we suggest that RXR agonism may be an effective
therapeutic approach for the treatment autoimmune disorders
particularly those such as MS where there is an imbalance in the
Treg/Th17 axis. MS is a particularly attractive target as RXR
agonists have also been reported to promote remyelination.DATA AVAILABILITY STATEMENT
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